On the subject of rigor in the study of amyloid β-protein assembly

Alzheimer's Research and Therapy

Volumn 5, Issue 4, 2013, Pages

  Teplow, David B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; ANTIBODY; MONOMER; OLIGOMER; POLYMER;

AMINO ACID SEQUENCE; CONFUSION; EPISTEMOLOGY; HUMAN; IATROGENIC DISEASE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; REVIEW; RIGOR;

EID: 84887977146     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt203     Document Type: Review

References (103)

1. Schwartz P, Amyloidosis-Cause and Manifestations of Senile Dementia Springfield: Charles C Thomas 1970 24009967
2. On an extraordinary, severe disease process of the cerebral cortex [in German]. Alzheimer A, Neurologisches Centralblatt 1906 23 1129 1136
3. Alzheimer's Disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Glenner GG, Wong CW, Biochem Biophys Res Commun 1984 122 1131 1135 10.1016/0006-291X(84)91209-9 6236805 (Pubitemid 14027629)
4. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Glenner GG, Wong CW, Biochem Biophys Res Commun 1984 120 885 890 10.1016/S0006-291X(84)80190-4 6375662 (Pubitemid 14104991)
5. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B, Nature 1987 325 733 736 10.1038/325733a0 2881207 (Pubitemid 17054046)
6. Amyloid β-protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Tanzi RE, Gusella JF, Watkins PC, Bruns GAB, St George-Hyslop PH, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL, Science 1987 235 880 884 10.1126/science.2949367 2949367 (Pubitemid 17019125)
7. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM, Proc Natl Acad Sci USA 1987 84 4190 4194 10.1073/pnas.84.12.4190 3035574 (Pubitemid 17090899)
8. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek D, Science 1987 235 877 880 10.1126/science.3810169 3810169 (Pubitemid 17019124)
9. Amyloid β-peptide is produced by cultured cells during normal metabolism. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Nature 1992 359 322 325 10.1038/359322a0 1383826
10. Electron microscopic observation on a fibrous component in amyloid of diverse origins. Cohen AS, Calkins E, Nature 1959 183 1202 1203 10.1038/1831202a0 13657054
11. Alzheimer's disease-an electron microscopical study. Kidd M, Brain 1964 87 307 320 10.1093/brain/87.2.307 14188276
12. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW, Brain Res 1991 563 311 314 10.1016/0006-8993(91)91553-D 1786545
13. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW, J Neurosci 1993 13 1676 1687 8463843 (Pubitemid 23095409)
14. Alzheimer's disease: the amyloid cascade hypothesis. Hardy JA, Higgins GA, Science 1992 256 184 185 10.1126/science.1566067 1566067
15. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Fitzpatrick AWP, Debelouchina GT, Bayro MJ, Clare DK, Caporini MA, Bajaj VS, Jaroniec CP, Wang L, Ladizhansky V, Müller SA, MacPhee CE, Waudby CA, Mott HR, De Simone A, Knowles TPJ, Saibil HR, Vendruscolo M, Orlova EV, Griffin RG, Dobson CM, Proc Natl Acad Sci USA 2013 110 5468 5473 10.1073/pnas.1219476110 23513222
16. On the nucleation and growth of amyloid β-protein fibrils: detection of nuclei and quantitation of rate constants. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB, Proc Natl Acad Sci USA 1996 93 1125 1129 10.1073/pnas.93.3.1125 8577726 (Pubitemid 26054370)
17. Kinetic theory of fibrillogenesis of amyloid β-protein. Lomakin A, Teplow DB, Kirschner DA, Benedek GB, Proc Natl Acad Sci USA 1997 94 7942 7947 10.1073/pnas.94.15.7942 9223292 (Pubitemid 27343754)
18. Kinetics and thermodynamics of amyloid fibril assembly. Wetzel R, Accounts Chem Res 2006 39 671 679 10.1021/ar050069h
19. Effect of spermidine on misfolding and interactions of alpha-synuclein. Krasnoslobodtsev AV, Peng J, Asiago JM, Hindupur J, Rochet JC, Lyubchenko YL, PLoS ONE 2012 7 38099 10.1371/journal.pone.0038099 22662273
20. Single molecule characterization of the interactions between amyloid-β peptides and the membranes of hippocampal cells. Narayan P, Ganzinger KA, McColl J, Weimann L, Meehan S, Qamar S, Carver JA, Wilson MR, St George-Hyslop P, Dobson CM, Klenerman D, J Am Chem Soc 2013 135 1491 1498 10.1021/ja3103567 23339742
21. Amyloid oligomers: formation and toxicity of Aβ oligomers. Sakono M, Zako T, FEBS J 2010 277 1348 1358 10.1111/j.1742-4658.2010.07568.x 20148964
22. Binding of apolipoprotein E inhibits the oligomer growth of amyloid-β peptide in solution as determined by fluorescence cross-correlation spectroscopy. Ly S, Altman R, Petrlova J, Lin Y, Hilt S, Huser T, Laurence TA, Voss JC, J Biol Chem 2013 288 11628 11635 10.1074/jbc.M112. 411900 23430745
23. Computer simulations of Alzheimer's amyloid β-protein folding and assembly. Urbanc B, Cruz L, Teplow DB, Stanley HE, Curr Alzheimer Res 2006 3 493 504 10.2174/156720506779025170 17168648 (Pubitemid 46066425)
24. Contrasting disease and nondisease protein aggregation by molecular simulation. Fawzi NL, Yap EH, Okabe Y, Kohlstedt KL, Brown SP, Head-Gordon T, Accounts Chem Res 2008 41 1037 1047 10.1021/ar800062k
25. Probing protein aggregation using simplified models and discrete molecular dynamics. Sharma S, Ding F, Dokholyan NV, Frontiers Biosci 2008 13 4795
26. G-F transformation of actin as a fibrous condensation. Oosawa F, Asakura S, Hotta K, Imai N, Ooi T, J Polymer Sci 1959 37 323 336 10.1002/pol.1959. 1203713202
27. Amyloid β-protein assembly and Alzheimer disease. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB, J Biol Chem 2009 284 4749 4753 18845536
28. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, Ann Neurol 1991 30 572 580 10.1002/ana.410300410 1789684
29. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-β protein precursor and amyloid-β Castellani RJ, Lee H, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA, J Alzheimer's Disease 2009 18 447 452 24008687
30. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L, Proc Natl Acad Sci USA 1999 96 3228 3233 10.1073/pnas.96.6.3228 10077666 (Pubitemid 29148873)
31. High-level neuronal expression of Aβ(1-42) in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L, J Neurosci 2000 20 4050 4058 10818140 (Pubitemid 30365675)
32. A specific amyloid-β protein assembly in the brain impairs memory. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH, Nature 2006 440 352 357 10.1038/nature04533 16541076
33. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe KH, Muchowski PJ, Mucke L, J Biol Chem 2007 282 23818 23828 10.1074/jbc.M701078200 17548355 (Pubitemid 47328006)
34. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB, J Biol Chem 1999 274 25945 25952 10.1074/jbc.274.36.25945 10464339 (Pubitemid 29418632)
35. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB, J Biol Chem 1997 272 22364 22372 10.1074/jbc.272.35.22364 9268388 (Pubitemid 27382873)
36. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L, Nat Neurosci 2001 4 887 893 10.1038/nn0901-887 11528419 (Pubitemid 32801591)
37. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby L, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C, Neurology 2003 61 46 54 10.1212/01.WNL.0000073623.84147.A8 12847155 (Pubitemid 36818745)
38. AN1792(QS-21)-201 study team: clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
39. Alzheimer's drug fails its first big clinical trial. Pollack A, New York Times 2012
40. Eli L, Eli Lilly and company announces top-line results on solanezumab phase 3 clinical trials in patients with Alzheimer's disease 2012 http://newsroom.lilly.com/releasedetail.cfm?releaseid=702211
41. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Lemere CA, Masliah E, Nature Rev Neurol 2010 6 108 119 10.1038/nrneurol.2009.219
42. Fibrillar amyloid-β-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease. Jana A, Pahan K, J Neurosci 2010 30 12676 12689 10.1523/JNEUROSCI.1243-10.2010 20861373
43. Koch R, Aetiology of Tuberculosis New York, NY: William R Jenkins 1890
44. Koch's postulates in relation to the work of Jacob Henle and Edwin Klebs. Carter KC, Med Hist 1985 29 353 374 10.1017/S0025727300044689 3903383 (Pubitemid 16244824)
45. Alzheimer's disease, a multifactorial disorder seeking multitherapies. Iqbal K, Grundke-Iqbal I, Alzheimer's Dementia 2010 6 420 424 10.1016/j.jalz.2010.04.006 24010015
46. The complex and multifactorial nature of Alzheimer's disease. Alkadhi K, Eriksen J, Cur Neuropharmacol 2011 9 586 10.2174/157015911798376235
47. The role of amyloidogenic protein oligomerization in neurodegenerative disease. Lotz GP, Legleiter J, J Molecular Medicine 2013 91 653 664 10.1007/s00109-013-1025-1
48. All roads lead to Rome? The multiple pathways of protein folding. Weissman JS, Chem Biol 1995 2 255 260 10.1016/1074-5521(95)90044-6 9383427
49. Polymer principles and protein folding. Dill KA, Protein Sci 1999 8 1166 1180 10.1110/ps.8.6.1166 10386867 (Pubitemid 29264947)
50. Multiple routes and structural heterogeneity in protein folding. Udgaonkar JB, Annu Rev Plant Physiol Plant Mol Biol 2008 37 489 510
51. The structural basis of protein folding and its links with human disease. Dobson CM, Phil Trans R Soc Lond B 2001 356 133 145 10.1098/rstb.2000.0758 (Pubitemid 32241461)
52. Amyloid β-protein monomer folding: free-energy surfaces reveal alloform-specific differences. Yang M, Teplow DB, J Mol Biol 2008 384 450 464 10.1016/j.jmb.2008.09.039 18835397
53. The structure of the Alzheimer amyloid β 10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent. Baumketner A, Shea JE, J Mole Biol 2007 366 275 285 10.1016/j.jmb.2006.11.015 (Pubitemid 46123329)
54. Folding of the 25 residue Aβ (12-36) peptide in TFE/water: temperature-dependent transition from a funneled free-energy landscape to a rugged one. Kamiya N, Mitomo D, Shea JE, Higo J, J Phys Chem B 2007 111 5351 5356 10.1021/jp067075v 17439167 (Pubitemid 46854527)
55. Folding stability of amyloid-β 40 monomer is an important determinant of the nucleation kinetics in fibrillization. Ni CL, Shi HP, Yu HM, Chang YC, Chen YR, FASEB J 2011 25 1390 1401 10.1096/fj.10-175539 21209058
56. Structural and kinetic features of amyloid β-protein fibrillogenesis. Teplow DB, Amyloid 1998 5 121 142 10.3109/13506129808995290 9686307 (Pubitemid 128691229)
57. Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Aβ fibril formation pathway. Lee S, Fernandez EJ, Good TA, Protein Sci 2007 16 723 732 10.1110/ps.062514807 17327396 (Pubitemid 46507001)
58. Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R, Proc Natl Acad Sci USA 2009 106 7443 7448 10.1073/pnas.0812033106 19376973
59. Comparing the folding free-energy landscapes of Aβ42 variants with different aggregation properties. Mitternacht S, Staneva I, Hard T, Irback A, Proteins Struct Funct Bioinform 2010 78 2600 2608
60. Molecular structures of quiescently grown and brain-derived polymorphic fibrils of the Alzheimer amyloid Aβ9-40 peptide: a comparison to agitated fibrils. Wu C, Bowers MT, Shea JE, PLoS Comput Biol 2010 6 1000693 10.1371/journal.pcbi.1000693 20221247
61. Solid-state NMR studies of amyloid fibril structure. Tycko R, Annu Rev Phys Chem 2011 62 279 299 10.1146/annurev-physchem-032210-103539 21219138
62. Quantum-theoretical re-interpretation of kinematic and mechanical relations [in German]. Heisenberg W, Zeitschrift fur Physik 1927 43 172 198 10.1007/BF01397280
63. Neurotoxic protein oligomers-what you see is not always what you get. Bitan G, Fradinger EA, Spring SM, Teplow DB, Amyloid 2005 12 88 95 10.1080/13506120500106958 16011984 (Pubitemid 40978716)
64. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB, Proc Natl Acad Sci USA 2003 100 330 335 10.1073/pnas.222681699 12506200 (Pubitemid 36078074)
65. Square A, Flatland: A Romance of Many Dimensions London: Seeley & Co 1884
66. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO, Nat Struct Mol Biol 2010 17 561 567 10.1038/nsmb.1799 20383142
67. 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R, Proc Natl Acad Sci USA 2005 102 17342 17347 10.1073/pnas.0506723102 16293696 (Pubitemid 41740868)
68. Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils. Paravastu AK, Leapman RD, Yau WM, Tycko R, Proc Natl Acad Sci USA 2008 105 18349 18354 10.1073/pnas.0806270105 19015532
69. Cross-β conformation in proteins. Geddes AJ, Parker KD, Atkins ED, Beighton E, J Mol Biol 1968 32 343 358 10.1016/0022-2836(68)90014-4 5643439
70. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, Madsen AO, Riekel C, Eisenberg D, Nature 2007 447 453 457 10.1038/nature05695 17468747 (Pubitemid 46816731)
71. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Harper JD, Wong SS, Lieber CM, Lansbury PT, Chem Biol 1997 4 119 125 10.1016/S1074-5521(97)90255-6 9190286 (Pubitemid 27161750)
72. Intrinsically disordered protein. Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, Oh JS, Oldfield CJ, Campen AM, Ratliff CM, Hipps KW, Ausio J, Nissen MS, Reeves R, Kang C, Kissinger CR, Bailey RW, Griswold MD, Chiu W, Garner EC, Obradovic Z, J Mol Graph Model 2001 19 26 59 10.1016/S1093- 3263(00)00138-8 11381529 (Pubitemid 32411501)
73. The rules of disorder or why disorder rules. Gsponer J, Babu MM, Prog Biophys Molecular Biol 2009 99 94 103 10.1016/j.pbiomolbio.2009.03.001
74. Intrinsically disordered proteins: a 10-year recap. Tompa P, Trends Biochem Sci 2012 37 509 516 10.1016/j.tibs.2012.08.004 22989858
75. Intrinsic disorder in protein interactions: insights from a comprehensive structural analysis. Fong JH, Shoemaker BA, Garbuzynskiy SO, Lobanov MY, Galzitskaya OV, Panchenko AR, PLoS Comp Biol 2009 5 1000316 10.1371/journal. pcbi.1000316
76. Wikipedia: Random walk http://en.wikipedia.org/wiki/Random-walk
77. Amyloid fibrils from muscle myoglobin. Fandrich M, Fletcher MA, Dobson CM, Nature 2001 410 165 166 10.1038/35065514 11242064 (Pubitemid 32216577)
78. Protein misfolding, functional amyloid, and human disease. Chiti F, Dobson CM, Annu Rev Biochem 2006 75 333 366 10.1146/annurev.biochem.75.101304. 123901 16756495 (Pubitemid 44118036)
79. Amyloid formation by globular proteins under native conditions. Chiti F, Dobson CM, Nature Chem Biol 2009 5 15 22
80. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Goldschmidt L, Teng PK, Riek R, Eisenberg D, Proc Natl Acad Sci USA 2010 107 3487 3492 10.1073/pnas.0915166107 20133726
81. Structure of the cross-β spine of amyloid-like fibrils. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ Riekel C, Grothe R, Eisenberg D, Nature 2005 435 773 778 10.1038/nature03680 15944695 (Pubitemid 40839722)
82. Molecular basis for passive immunotherapy of Alzheimer's disease. Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C, Proc Natl Acad Sci USA 2007 104 15659 15664 10.1073/pnas.0705888104 17895381 (Pubitemid 350035356)
83. Structural correlates of antibodies associated with acute reversal of amyloid β-related behavioral deficits in a mouse model of Alzheimer disease. Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, Comery TA, Diep L, Gill D, Johnson-Wood K, Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-Prenner I, Piot N, Walker D, Widom A, Pangalos MN, Seubert P, Jacobsen JS, Schenk D, Weis WI, J Biol Chem 2010 285 3417 3427 10.1074/jbc.M109.045187 19923222
84. The war on heterophilic antibody interference. Bjerner J, Børmer OP, Nustad K, Clin Chem 2005 51 9 11 15613705 (Pubitemid 40024005)
85. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. Sehlin D, Sollvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, Pettersson FE, Englund H, J Alzheimers Dis 2010 21 1295 1301 21504116
86. Review: history of the amyloid fibril. Sipe JD, Cohen AS, J Struc Biol 2000 130 88 98 10.1006/jsbi.2000.4221
87. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM, Nature Med 2006 12 856 861 10.1038/nm1438 16799555 (Pubitemid 44050079)
88. Amyloid-β (1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, Conboy E, Hartigan D, Rosenberry TL, Biochem 2007 46 12451 12462 10.1021/bi701213s (Pubitemid 350027406)
89. Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples. Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, Johanssen T, McLean CA, Kok WM, Hutton CA, Fodero-Tavoletti M, Masters CL, Villemagne VL, Barnham KJ, Acta Neuropathol 2013 125 549 564 10.1007/s00401-013-1083-z 23354835
90. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ, Nature Med 2008 14 837 842 10.1038/nm1782 18568035
91. Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM, Alzheimer Dis Frontotemporal Dementia Meth Mole Biol 2011 670 33 44
92. Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. Moore B, Chakrabarty P, Levites Y, Kukar T, Baine A, Moroni T, Ladd T, Das P, Dickson D, Golde T, Alzheimer's Res Therapy 2012 4 18 10.1186/alzrt121 24010015
93. The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia. McDonald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM, Brain 2010 133 1328 1341 10.1093/brain/awq065 20403962
94. Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, Noda M, Fukunari A, Muramatsu S, Itokazu Y, Sato K, Takahashi H, Teplow DB, Nabeshima Y, Katika A, Imahori K, Hoshi M, J Biol Chem 2009 284 32895 32905 10.1074/jbc.M109.000208 19759000
95. Comparing antibody and small-molecule therapies for cancer. Imai K, Takaoka A, Nature Rev Cancer 2006 6 714 727 10.1038/nrc1913 (Pubitemid 44286003)
96. Immunohistochemical detection of dityrosine in lipofuscin pigments in the aged human brain. Kato Y, Maruyama W, Naoi M, Hashizume Y, Osawa T, FEBS Lett 1998 439 231 234 10.1016/S0014-5793(98)01372-6 9845328 (Pubitemid 28546650)
97. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA, J Neuroscience 1998 18 8126 8132 (Pubitemid 28464991)
98. A general statement of the laws of chemical equilibria [in French]. Le Chatelier HL, Comptes Rendus Académie des Sci 1884 99 786 789
99. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Benilova I, Karran E, De Strooper B, Nature Neurosci 2012 15 349 357 10.1038/nn.3028 22286176
100. Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Stöhr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB, Giles K, Proc Natl Acad Sci USA 2012 109 11025 11030 10.1073/pnas. 1206555109 22711819
101. De novo induction of amyloid-β deposition in vivo. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C, Mol Psychiatry 2012 17 1347 1353 10.1038/mp.2011.120 21968933
102. Kuhn TS, The Structure of Scientific Revolutions Chicago and London: University of Chicago Press 1970
103. Structure-neurotoxicity relationships of amyloid β-protein oligomers. Ono K, Condron MM, Teplow DB, Proc Natl Acad Sci USA 2009 106 14745 14750 10.1073/pnas.0905127106 19706468